{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:56:26Z","timestamp":1787601386201,"version":"build-2736575974"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11864-025-01304-w","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:25:41Z","timestamp":1741231541000},"page":"227-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies"],"prefix":"10.1007","volume":"26","author":[{"given":"Demitrios","family":"Dedousis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Gadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Van Galen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"11","key":"1304_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/s1470-2045(02)00899-9","volume":"3","author":"H Joensuu","year":"2002","unstructured":"Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002;3(11):655\u201364. https:\/\/doi.org\/10.1016\/s1470-2045(02)00899-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1304_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/cncr.20862","volume":"103","author":"B Nilsson","year":"2005","unstructured":"Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era\u2013a population-based study in western Sweden. Cancer. 2005;103(4):821\u20139. https:\/\/doi.org\/10.1002\/cncr.20862.","journal-title":"Cancer"},{"issue":"7","key":"1304_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"MC Heinrich","year":"2017","unstructured":"Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, et al. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017;3(7):944\u201352. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6728.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1304_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2017.74.9705","volume":"36","author":"M von Mehren","year":"2018","unstructured":"von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018;36(2):136\u201343. https:\/\/doi.org\/10.1200\/JCO.2017.74.9705.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1304_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"KA Janeway","year":"2011","unstructured":"Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108(1):314\u20138. https:\/\/doi.org\/10.1073\/pnas.1009199108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"1304_CR6","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22(18):3813\u201325. https:\/\/doi.org\/10.1200\/JCO.2004.05.140.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1304_CR7","doi-asserted-by":"publisher","first-page":"e7668","DOI":"10.1097\/MD.0000000000007668","volume":"96","author":"W Liu","year":"2017","unstructured":"Liu W, Zeng X, Wu X, He J, Gao J, Shuai X, et al. Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: A single-institutional experience in China. Medicine (Baltimore). 2017;96(32):e7668. https:\/\/doi.org\/10.1097\/MD.0000000000007668.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1304_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","volume":"16","author":"B Pasini","year":"2008","unstructured":"Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79\u201388. https:\/\/doi.org\/10.1038\/sj.ejhg.5201904.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"1304_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/gim.2014.115","volume":"17","author":"MA Pantaleo","year":"2015","unstructured":"Pantaleo MA, Lolli C, Nannini M, Astolfi A, Indio V, Saponara M, et al. Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genet Med. 2015;17(5):391\u20135. https:\/\/doi.org\/10.1038\/gim.2014.115.","journal-title":"Genet Med"},{"issue":"7","key":"1304_CR10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular Subtypes of KIT\/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2(7):922\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0256.","journal-title":"JAMA Oncol"},{"key":"1304_CR11","unstructured":"Else T, Greenberg S, Fishbein L. Hereditary paraganglioma-pheochromocytoma syndromes. In:\u00a0Adam MP, Feldman J, Mirzaa GM, et al, editors.\u00a0GeneReviews\u00ae. Seattle: University of Washington; 1993\u20132025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1548\/."},{"issue":"6","key":"1304_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","volume":"3","author":"JK Killian","year":"2013","unstructured":"Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013;3(6):648\u201357. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0092.","journal-title":"Cancer Discov"},{"issue":"4","key":"1304_CR13","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1038\/emm.2017.5","volume":"49","author":"J An","year":"2017","unstructured":"An J, Rao A, Ko M. TET family dioxygenases and DNA demethylation in stem cells and cancers. Exp Mol Med. 2017;49(4):e323. https:\/\/doi.org\/10.1038\/emm.2017.5.","journal-title":"Exp Mol Med"},{"issue":"12","key":"1304_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326\u201338. https:\/\/doi.org\/10.1101\/gad.191056.112.","journal-title":"Genes Dev"},{"key":"1304_CR15","doi-asserted-by":"publisher","first-page":"175883592110232","DOI":"10.1177\/17588359211023278","volume":"13","author":"M Nannini","year":"2021","unstructured":"Nannini M, Rizzo A, Indio V, Schipani A, Astolfi A, Pantaleo MA. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021;13:17588359211023278. https:\/\/doi.org\/10.1177\/17588359211023278.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1304_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77\u201385. https:\/\/doi.org\/10.1016\/j.ccr.2004.11.022.","journal-title":"Cancer Cell"},{"issue":"4\u20135","key":"1304_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.semcdb.2005.04.001","volume":"16","author":"JL Ruas","year":"2005","unstructured":"Ruas JL, Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin Cell Dev Biol. 2005;16(4\u20135):514\u201322. https:\/\/doi.org\/10.1016\/j.semcdb.2005.04.001.","journal-title":"Semin Cell Dev Biol"},{"issue":"5\u20136","key":"1304_CR18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/s0006-2952(02)01168-1","volume":"64","author":"G Semenza","year":"2002","unstructured":"Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol. 2002;64(5\u20136):993\u20138. https:\/\/doi.org\/10.1016\/s0006-2952(02)01168-1.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"1304_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10555-019-09818-0","volume":"38","author":"P Neppala","year":"2019","unstructured":"Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, et al. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. Cancer Metastasis Rev. 2019;38(3):525\u201335. https:\/\/doi.org\/10.1007\/s10555-019-09818-0.","journal-title":"Cancer Metastasis Rev"},{"key":"1304_CR20","doi-asserted-by":"publisher","unstructured":"Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules. 2020;10(12), https:\/\/doi.org\/10.3390\/biom10121673.","DOI":"10.3390\/biom10121673"},{"issue":"4","key":"1304_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4161\/cc.8.4.7657","volume":"8","author":"VD Acevedo","year":"2009","unstructured":"Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009;8(4):580\u20138. https:\/\/doi.org\/10.4161\/cc.8.4.7657.","journal-title":"Cell Cycle"},{"key":"1304_CR22","doi-asserted-by":"publisher","unstructured":"Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, et al. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. Cancer Cell. 2019;35(5):738\u2013751 e739, https:\/\/doi.org\/10.1016\/j.ccell.2019.04.006.","DOI":"10.1016\/j.ccell.2019.04.006"},{"key":"1304_CR23","doi-asserted-by":"publisher","unstructured":"Dai S, Zhou Z, Chen Z, Xu G, Chen Y. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells. 2019;8(6), https:\/\/doi.org\/10.3390\/cells8060614.","DOI":"10.3390\/cells8060614"},{"issue":"7","key":"1304_CR24","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0699.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1304_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116\u201329. https:\/\/doi.org\/10.1038\/nrc2780.","journal-title":"Nat Rev Cancer"},{"key":"1304_CR26","unstructured":"Van Galen J.\u00a0Created in BioRender.2025. https:\/\/biorender.com\/d15x998. Accessed 17 Jan 2025."},{"key":"1304_CR27","unstructured":"SUTENT\u00ae (sunitinib malate) [tablets]. New York, NY: Pfizer; 2021. U.S. Food and Drug Administration website.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021938s039lbledt.pdf. Accessed 15 Nov 2024."},{"key":"1304_CR28","unstructured":"VOTRIENT\u00ae (pazopanib) [tablets]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; 2024. U.S. Food and Drug Administration website. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/votrient.pdf. Accessed 15 Nov 2024."},{"key":"1304_CR29","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines \u00ae) Gastrointestinal Stromal Tumors Version 2.2024. NCCN n.d. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453. Accessed 3 Jan 2025."},{"issue":"9","key":"1304_CR30","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/annonc\/mdw228","volume":"27","author":"E Ben-Ami","year":"2016","unstructured":"Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016;27(9):1794\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdw228.","journal-title":"Ann Oncol"},{"issue":"1","key":"1304_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdt484","volume":"25","author":"KN Ganjoo","year":"2014","unstructured":"Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014;25(1):236\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdt484.","journal-title":"Ann Oncol"},{"issue":"7","key":"1304_CR32","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/pbc.21909","volume":"52","author":"KA Janeway","year":"2009","unstructured":"Janeway KA, Albritton KH, Van Den Abbeele AD, D\u2019Amato GZ, Pedrazzoli P, Siena S, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009;52(7):767\u201371. https:\/\/doi.org\/10.1002\/pbc.21909.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1304_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1304_CR34","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1304_CR35","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"issue":"11","key":"1304_CR36","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1007\/s00277-024-06027-w","volume":"103","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Huang J, Wang Y, Han Y, Xue S, Yang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. 2024;103(11):4643\u20138. https:\/\/doi.org\/10.1007\/s00277-024-06027-w.","journal-title":"Ann Hematol"},{"issue":"1","key":"1304_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245\u201355. https:\/\/doi.org\/10.1002\/ijc.25864.","journal-title":"Int J Cancer"},{"key":"1304_CR38","doi-asserted-by":"publisher","unstructured":"Brahmi M, Dufresne A, Pattee A, Vanacker H, Meurgey A, Pissaloux D, et al. 1975P Systemic therapy for KIT\/PDGFRA wild-type GIST. Annals of Oncology. 2023;34, https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1204.","DOI":"10.1016\/j.annonc.2023.09.1204"},{"key":"1304_CR39","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT02638766, Single Agent Regorafenib in First-line for Metastatic\/Unresectable KIT\/PDGFR Wild Type GIST (REGISTRI). 2015 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | Single Agent Regorafenib in First-line for Metastatic\/Unresectable KIT\/PDGFR Wild Type GIST | ClinicalTrials.gov."},{"issue":"1","key":"1304_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12943-023-01832-9","volume":"22","author":"J Martin-Broto","year":"2023","unstructured":"Martin-Broto J, Valverde C, Hindi N, Vincenzi B, Martinez-Trufero J, Grignani G, et al. REGISTRI: Regorafenib in first-line of KIT\/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. Mol Cancer. 2023;22(1):127. https:\/\/doi.org\/10.1186\/s12943-023-01832-9.","journal-title":"Mol Cancer"},{"key":"1304_CR41","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT06087263, Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. 2023 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. | ClinicalTrials.gov."},{"key":"1304_CR42","doi-asserted-by":"publisher","unstructured":"Le Cesne A, Cropet C, Gautier J, Gagne S, Francourt K, Hernandez C, et al. LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.\u00a0J Clin Oncol. 2020;38(15).\u00a0https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.TPS11568","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS11568"},{"key":"1304_CR43","unstructured":"Burgoyne A. An open-label, phase II efficacy study of temozolomide in advanced succinate dehydrogenase-mutant\/deficient gastrointestinal stromal tumor.\u00a02023 CTOS. Oral presentation. Dublin; 2023."},{"issue":"2","key":"1304_CR44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","volume":"29","author":"JA Ligon","year":"2023","unstructured":"Ligon JA, Sundby RT, Wedekind MF, Arnaldez FI, Del Rivero J, Wiener L, et al. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. Clin Cancer Res. 2023;29(2):341\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2168.","journal-title":"Clin Cancer Res"},{"issue":"34","key":"1304_CR45","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","volume":"40","author":"S Bauer","year":"2022","unstructured":"Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schoffski P, et al. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label. Phase III Trial J Clin Oncol. 2022;40(34):3918\u201328. https:\/\/doi.org\/10.1200\/JCO.22.00294.","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"7","key":"1304_CR46","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","volume":"21","author":"JY Blay","year":"2020","unstructured":"Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923\u201334. https:\/\/doi.org\/10.1016\/S1470-2045(20)30168-6.","journal-title":"Lancet Oncol"},{"key":"1304_CR47","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03673501, A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (INTRIGUE). 2023 [cited 2025 Jan 3]; [about 4 screens]. Available from: http:\/\/clinicaltrials.gov\/ct\/show\/NCT00287391?order=1."},{"issue":"4","key":"1304_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/14737140.2022.2039123","volume":"22","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, et al. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther. 2022;22(4):383\u2013400. https:\/\/doi.org\/10.1080\/14737140.2022.2039123.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1304_CR49","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT04193553, Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib\/ Sunitinib Failure (LENVAGIST). 2019 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib\/Sunitinib Failure | ClinicalTrials.gov."},{"issue":"4","key":"1304_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Olverembatinib: First Approval. Drugs. 2022;82(4):469\u201375. https:\/\/doi.org\/10.1007\/s40265-022-01680-9.","journal-title":"Drugs"},{"issue":"1","key":"1304_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Q Jiang","year":"2022","unstructured":"Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 2022;15(1):113. https:\/\/doi.org\/10.1186\/s13045-022-01334-z.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1304_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in \u201cWild-Type\u201d gastrointestinal stromal tumors. J Transl Med. 2016;14(1):339. https:\/\/doi.org\/10.1186\/s12967-016-1075-6.","journal-title":"J Transl Med"},{"key":"1304_CR53","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03594422, A Study of HQP1351 in Patients With GIST or Other Solid Tumors. 2018 [cited 2025 Jan 3]; [about 4 screens]. Available from: http:\/\/clinicaltrials.gov\/ct\/show\/NCT00287391?order=1."},{"key":"1304_CR54","doi-asserted-by":"publisher","unstructured":"Qiu H, Zhou Z, Zhou Y, Chen J, et al. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. In: 2024 ASCO. Abstract. J Clin Oncol 2024;42. Chicago.\u00a0https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.11502","DOI":"10.1200\/JCO.2024.42.16_suppl.11502"},{"key":"1304_CR55","doi-asserted-by":"publisher","first-page":"S1032","DOI":"10.1016\/j.annonc.2024.08.1814","volume":"35","author":"H Qiu","year":"2024","unstructured":"Qiu H, Yang C, Zhou Z, Zhou Y, Wan X, Li K, et al. 1722MO Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA). Ann Oncol. 2024;35:S1032. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1814.","journal-title":"Ann Oncol"},{"key":"1304_CR56","doi-asserted-by":"publisher","first-page":"S1053","DOI":"10.1016\/j.annonc.2023.09.1202","volume":"34","author":"H Qiu","year":"2023","unstructured":"Qiu H, Zhou Z, Zhou Y, Wan X, Li N, Tao K, et al. 1973P Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). Ann Oncol. 2023;34:S1053\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1202.","journal-title":"Ann Oncol"},{"key":"1304_CR57","doi-asserted-by":"crossref","unstructured":"Xiong Y, Liang E, Min P, Yu H, Wu B, Zhai G, et al. Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms. In: 2024 AACR. Abstract. San Diego; 2024.","DOI":"10.1158\/1538-7445.AM2024-1971"},{"issue":"13","key":"1304_CR58","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","volume":"30","author":"A Morin","year":"2020","unstructured":"Morin A, Goncalves J, Moog S, Castro-Vega LJ, Job S, Buffet A, et al. TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2alpha-Driven Mesenchymal Transition. Cell Rep. 2020;30(13):4551-4566 e4557. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.022.","journal-title":"Cell Rep."},{"issue":"10","key":"1304_CR59","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-03-0715","volume":"10","author":"CR Antonescu","year":"2004","unstructured":"Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH, et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res. 2004;10(10):3282\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0715.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1304_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1304_CR61","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"C Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207\u201319. https:\/\/doi.org\/10.1111\/cas.13536.","journal-title":"Cancer Sci"},{"issue":"11","key":"1304_CR62","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1569\u201375. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3039.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1304_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","volume":"9","author":"Y Sun","year":"2016","unstructured":"Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. https:\/\/doi.org\/10.1186\/s13045-016-0332-8.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"1304_CR64","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1158\/1078-0432.CCR-20-2950","volume":"27","author":"D Li","year":"2021","unstructured":"Li D, Chi Y, Chen X, Ge M, Zhang Y, Guo Z, et al. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial. Clin Cancer Res. 2021;27(13):3567\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2950.","journal-title":"Clin Cancer Res"},{"key":"1304_CR65","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT04595747, Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST). 2022 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | ClinicalTrials.gov."},{"issue":"4","key":"1304_CR66","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1093\/oncolo\/oyac271","volume":"28","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Zeng C, Sun X, Zhang J, Qu H, Zhang X, et al. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter. In Vitro Study Oncologist. 2023;28(4):e191\u20137. https:\/\/doi.org\/10.1093\/oncolo\/oyac271.","journal-title":"In Vitro Study Oncologist"},{"key":"1304_CR67","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3389\/fonc.2020.00664","volume":"10","author":"J Ma","year":"2020","unstructured":"Ma J, Song Y, Shou J, Bai Y, Li H, Xie X, et al. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. Front Oncol. 2020;10:664. https:\/\/doi.org\/10.3389\/fonc.2020.00664.","journal-title":"Front Oncol"},{"issue":"5","key":"1304_CR68","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ijc.32224","volume":"145","author":"S Grunewald","year":"2019","unstructured":"Grunewald S, Politz O, Bender S, Heroult M, Lustig K, Thuss U, et al. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019;145(5):1346\u201357. https:\/\/doi.org\/10.1002\/ijc.32224.","journal-title":"Int J Cancer"},{"issue":"3","key":"1304_CR69","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JCO.21.02303","volume":"41","author":"CN Sternberg","year":"2023","unstructured":"Sternberg CN, Petrylak DP, Bellmunt J, Nishiyama H, Necchi A, Gurney H, et al. FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1\/3 mRNA Expression. J Clin Oncol. 2023;41(3):629\u201339. https:\/\/doi.org\/10.1200\/JCO.21.02303.","journal-title":"J Clin Oncol"},{"issue":"7781","key":"1304_CR70","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-019-1668-3","volume":"575","author":"WA Flavahan","year":"2019","unstructured":"Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229\u201333. https:\/\/doi.org\/10.1038\/s41586-019-1668-3.","journal-title":"Nature"},{"key":"1304_CR71","unstructured":"Merriam P. A phase 2 study of rogaratinib (BAY 1163877) in soft tissue sarcomas: initial results in cohort of patients with Succinate Dehydrogenase (SDH)-Ddeficient Gastrointestinal Stromal Tumor (GIST).\u00a0Dublin: 2023 CTOS. Oral presentation. Presented November 1, 2023."},{"issue":"2","key":"1304_CR72","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/jm00368a016","volume":"27","author":"MF Stevens","year":"1984","unstructured":"Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E, et al. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one, a novel broad-spectrum antitumor agent. J Med Chem. 1984;27(2):196\u2013201. https:\/\/doi.org\/10.1021\/jm00368a016.","journal-title":"J Med Chem"},{"issue":"12","key":"1304_CR73","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/cncr.11875","volume":"98","author":"JC Trent","year":"2003","unstructured":"Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98(12):2693\u20139. https:\/\/doi.org\/10.1002\/cncr.11875.","journal-title":"Cancer"},{"key":"1304_CR74","doi-asserted-by":"publisher","unstructured":"Minniti G, Lombardi G, Paolini S. Glioblastoma in Elderly Patients: Current Management and Future Perspectives. Cancers (Basel). 2019;11(3). https:\/\/doi.org\/10.3390\/cancers11030336.","DOI":"10.3390\/cancers11030336"},{"issue":"11","key":"1304_CR75","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711\u201320. https:\/\/doi.org\/10.1002\/ijc.28913.","journal-title":"Int J Cancer"},{"issue":"1","key":"1304_CR76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/jcp-2022-208462","volume":"77","author":"OT Giger","year":"2023","unstructured":"Giger OT, Ten Hoopen R, Shorthouse D, Abdullahi S, Bulusu VR, Jadhav S, et al. Preferential MGMT hypermethylation in SDH-deficient wild-type GIST. J Clin Pathol. 2023;77(1):34\u20139. https:\/\/doi.org\/10.1136\/jcp-2022-208462.","journal-title":"J Clin Pathol"},{"issue":"1","key":"1304_CR77","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-21-2092","volume":"28","author":"M Yebra","year":"2022","unstructured":"Yebra M, Bhargava S, Kumar A, Burgoyne AM, Tang CM, Yoon H, et al. Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clin Cancer Res. 2022;28(1):187\u2013200. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2092.","journal-title":"Clin Cancer Res"},{"key":"1304_CR78","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05661643,The Efficacy and Safety of Temozolomide in SDH-deficient GIST (GIST). 2022 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | The Efficacy and Safety of Temozolomide in SDH-deficient GIST | ClinicalTrials.gov."},{"key":"1304_CR79","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03556384, Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant\/Deficient Gastrointestinal Stromal Tumor (GIST). 2018 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant\/Deficient Gastrointestinal Stromal Tumor (GIST) | ClinicalTrials.gov."},{"issue":"8","key":"1304_CR80","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","volume":"50","author":"PL Sulkowski","year":"2018","unstructured":"Sulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, et al. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet. 2018;50(8):1086\u201392. https:\/\/doi.org\/10.1038\/s41588-018-0170-4.","journal-title":"Nat Genet"},{"issue":"1","key":"1304_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/1078-0432.CCR-21-0878","volume":"28","author":"AS Singh","year":"2022","unstructured":"Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M, et al. A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. Clin Cancer Res. 2022;28(1):84\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0878.","journal-title":"Clin Cancer Res"},{"key":"1304_CR82","doi-asserted-by":"publisher","unstructured":"Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, et al.Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J Immunother Cancer. 2022;10(6). https:\/\/doi.org\/10.1136\/jitc-2022-004495.","DOI":"10.1136\/jitc-2022-004495"},{"key":"1304_CR83","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03165721, A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST, Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer. 2017 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | ClinicalTrials.gov."},{"key":"1304_CR84","unstructured":"Kalladi S.\u00a0Combination treatment with temozolomide and the death receptor-5 agonist INBRX-109 effectively targets succinate dehydrogenase deficient gastrointestinal stromal tumor. Dublin: 2023 CTOS. Abstract. Presented November 1\u20134, 2023."},{"key":"1304_CR85","doi-asserted-by":"publisher","first-page":"1384795","DOI":"10.3389\/fmolb.2024.1384795","volume":"11","author":"Z Gamie","year":"2024","unstructured":"Gamie Z, Krippner-Heidenreich A, Gerrand C, Rankin KS. Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature. Front Mol Biosci. 2024;11:1384795. https:\/\/doi.org\/10.3389\/fmolb.2024.1384795.","journal-title":"Front Mol Biosci"},{"issue":"16","key":"1304_CR86","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, et al. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody. Chondrosarcoma Clin Cancer Res. 2023;29(16):2988\u20133003. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0974.","journal-title":"Chondrosarcoma Clin Cancer Res"},{"key":"1304_CR87","unstructured":"Kalladi S.\u00a0PERK Endoplasmic Reticulum (ER) Stress is a Key Modulator of TMZ-Induced Activation of the DR5 Mediated Apoptotic Pathway in Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumor (GIST): Phase I Study of TMZ + INBRX-109 in SDH-Deficient Cancers.\u00a0San Diego: 2024 CTOS. Oral Presentation. Presented November 13\u201316, 2024."},{"key":"1304_CR88","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03715933, Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas. 2018 [cited 2025 Jan 3]; [about 4 screens]. Available from: http:\/\/clinicaltrials.gov\/ct\/show\/NCT00287391?order=1."},{"key":"1304_CR89","unstructured":"Somaiah N.\u00a0Phase I Study of TMZ + INBRX-109 in SDH-Deficient Cancers. San Diego: 2024 CTOS. Oral presentation. Presented November 13\u201316, 2024."},{"issue":"3","key":"1304_CR90","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41419-024-06571-3","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Yu J, Li Y, Shi H, Jiao X, Liu X, et al. Deciphering the tumor immune microenvironment of imatinib-resistance in advanced gastrointestinal stromal tumors at single-cell resolution. Cell Death Dis. 2024;15(3):190. https:\/\/doi.org\/10.1038\/s41419-024-06571-3.","journal-title":"Cell Death Dis"},{"key":"1304_CR91","doi-asserted-by":"publisher","first-page":"715727","DOI":"10.3389\/fimmu.2021.715727","volume":"12","author":"M Roulleaux Dugage","year":"2021","unstructured":"Roulleaux Dugage M, Jones RL, Trent J, Champiat S, Dumont S. Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors. Front Immunol. 2021;12:715727. https:\/\/doi.org\/10.3389\/fimmu.2021.715727.","journal-title":"Front Immunol"},{"issue":"12","key":"1304_CR92","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1158\/1078-0432.CCR-16-2349","volume":"23","author":"SP D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo SP, Shoushtari AN, Keohan ML, Dickson MA, Gounder MM, Chi P, et al. Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017;23(12):2972\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2349.","journal-title":"Clin Cancer Res"},{"key":"1304_CR93","doi-asserted-by":"publisher","unstructured":"Chen JL, Mahoney MR, George S, Antonescu CR, DA, L, BA, VT. A multicenter phase II study of nivolumab +\/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts. Journal of Clinical Oncology. 2020;38, https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.11511.","DOI":"10.1200\/JCO.2020.38.15_suppl.11511"},{"key":"1304_CR94","doi-asserted-by":"publisher","first-page":"113351","DOI":"10.1016\/j.ejca.2023.113351","volume":"194","author":"O Klein","year":"2023","unstructured":"Klein O, Palmer J, Behren A, Cebon J, Kee D. Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour. Eur J Cancer. 2023;194:113351. https:\/\/doi.org\/10.1016\/j.ejca.2023.113351.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1304_CR95","doi-asserted-by":"publisher","first-page":"1710064","DOI":"10.1080\/2162402X.2019.1710064","volume":"9","author":"BA Schroeder","year":"2020","unstructured":"Schroeder BA, Kohli K, O\u2019Malley RB, Kim TS, Jones RL, Pierce RH, et al. Durable tumor regression in highly refractory metastatic KIT\/PDGFRA wild-type GIST following treatment with nivolumab. Oncoimmunology. 2020;9(1):1710064. https:\/\/doi.org\/10.1080\/2162402X.2019.1710064.","journal-title":"Oncoimmunology"},{"key":"1304_CR96","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05152472, A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST). 2021 [cited 2025 Jan 3]; [about 4 screens]. Available from: Study Details | A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | ClinicalTrials.gov."},{"key":"1304_CR97","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.3332\/ecancer.2023.1497","volume":"17","author":"AK Baa","year":"2023","unstructured":"Baa AK, Rastogi S, Fernandes S, Shrivastava S, Yadav R, Barwad A, et al. Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India. Ecancermedicalscience. 2023;17:1497. https:\/\/doi.org\/10.3332\/ecancer.2023.1497.","journal-title":"Ecancermedicalscience"},{"issue":"4","key":"1304_CR98","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.21037\/jgo-24-501","volume":"15","author":"SR Perati","year":"2024","unstructured":"Perati SR, Blakely AM. Modern times call for modernized treatment strategies for advanced gastrointestinal stromal tumors. J Gastrointest Oncol. 2024;15(4):2013\u20135. https:\/\/doi.org\/10.21037\/jgo-24-501.","journal-title":"J Gastrointest Oncol"}],"updated-by":[{"DOI":"10.1007\/s11864-025-01315-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01304-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01304-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01304-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:45:08Z","timestamp":1744350308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01304-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1304"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01304-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11864-025-01315-7","asserted-by":"object"}]},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"15 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, the author\u2019s name Margaret von Mehren was incorrectly written as Margaret von Meren.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11864-025-01315-7","URL":"https:\/\/doi.org\/10.1007\/s11864-025-01315-7","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Demitrios Dedousis has served as a personal consultant for Exelixis. Elyse Gadra has declared that she has no conflicts of interest. Joseph Van Galen has received the Fox Chase Cancer Center Trainee Research Grant, royalties from the NIH Technology Transfer office, payment for lectures at Exelixis and Plexus Communications, and support for attending the 2024 National Comprehensive Cancer Network\u2019s annual meeting. Margaret von Mehren declares that Fox Chase Cancer Center received support for Phase II Efficacy Study of Temozolomide in Advanced Succinate Dehydrogenase-Mutant\/Deficient Gastrointestinal Stromal Tumor, which is discussed in this manuscript. Margaret von Mehren also declares that she sits as the Chair of the NCCN Soft Tissue Sarcoma Panel and the Co-Chair of Mentoring Committee for the Connective Tissue Oncology Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}